Use of biosimilars in paediatric inflammatory bowel disease: A position statement of the ESPGHAN paediatric IBD porto group

Keyphrases

• Position Statement 100%
• Porto 100%
• Pediatric Inflammatory Bowel Disease 100%
• ESPGHAN 100%
• Biosimilar 100%
• Inflammatory Bowel Disease 66%
• Monoclonal Antibody 33%
• Safety Self-efficacy 33%
• Clinical Data 33%
• Surveillance Program 33%
• Post-marketing Surveillance 33%
• Biological Drugs 33%
• Easy Access 33%
• Immunogenicity 33%
• Rheumatologic Diseases 33%
• Biopharmaceuticals 33%
• Drug Costs 33%

Medicine and Dentistry

• Inflammatory Bowel Disease 100%
• Biosimilar 100%
• Pediatrics 100%
• Disease 25%
• Monoclonal Antibody 25%
• Immunogenicity 25%
• Biopharmaceuticals 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Biosimilar Agent 100%
• Disease 25%
• Monoclonal Antibody 25%
• Postmarketing Surveillance 25%
• Immunogenicity 25%